Journal of Clinical Endocrinology & Metabolism, Vol 80, 3180-3184, Copyright © 1995 by Endocrine Society

ARTICLES

Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection

M Pombo, J Barreiro, A Penalva, R Peino, C Dieguez and FF Casanueva
Department of Pediatrics, School of Medicine, University of Santiago de Compostela, Spain.

GH-releasing peptide (GHRP-6; His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic compound that releases GH in a specific and dose-related manner through mechanisms and a point of action that are mostly unknown, but different from those of GHRH. In man, GHRP-6 is more efficacious than GHRH, and a striking synergistic action occurs when both compounds are administered together. To explain such a synergistic effect, it has been postulated, but not proven, that GHRP-6 acts through a double mechanism, with actions exerted at the pituitary and the hypothalamic level. On the other hand, patients with the syndrome of GH deficiency due to perinatal pituitary stalk transection have any hypothalamic factor nonoperandi. The aim of the present study was 3- fold: 1) to further understand how relevant, if at all, the hypothalamic action of GHRP-6 is for GH regulation; 2) to evaluate whether GHRP-6 plus GHRH could be a suitable diagnostic tool in children with pituitary stalk transection; and 3) to compare these results with similar published studies performed in patients with hypothalamo-pituitary disconnection, who developed the disease as adults. Seven patients with GH deficiency and different degrees of panhypopituitarism due to perinatal pituitary stalk transection and 7 age- and sex-matched normal controls were studied. The subjects underwent 3 different tests on separate occasions, being challenged with GHRH (1 microgram/kg, iv), GHRP-6 (1 microgram/kg, iv), or GHRH plus GHRP-6. GH was analyzed as the area under the curve (mean +/- SE; micrograms per L/90 min). In normal subjects, GH secretion was 1029 +/- 202 after GHRH treatment, 1221 +/- 345 after GHRP-6, and 3542 +/- 650 after GHRH plus GHRP-6; the latter value was significantly (P < 0.05) higher than the secretion elicited by GHRH or GHRP-6 alone. In the group of patients with perinatal pituitary stalk transection, the level of GH after GHRH treatment was 116 +/- 22 and was even more reduced (P < 0.05) after GHRP-6 treatment (37 +/- 8). After GHRH plus GHRP-6, GH secretion in those patients was 177 +/- 27, significantly higher (P < 0.05) than the secretion induced by either GHRH or GHRP-6 alone. Individually examined, none of the patients tested with the most potent stimulus known to date (GHRH plus GHRP-6) exhibited GH secretion greater than 5 micrograms/L.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				F. F. Casanueva, J. P. Camina, M. C. Carreira, Y. Pazos, J. L. Varga, and A. V. Schally Growth hormone-releasing hormone as an agonist of the ghrelin receptor GHS-R1a PNAS, December 23, 2008; 105(51): 20452 - 20457. [Abstract] [Full Text] [PDF]

				R. D. Kineman and R. M. Luque Evidence that Ghrelin Is as Potent as Growth Hormone (GH)-Releasing Hormone (GHRH) in Releasing GH from Primary Pituitary Cell Cultures of a Nonhuman Primate (Papio anubis), Acting through Intracellular Signaling Pathways Distinct from GHRH Endocrinology, September 1, 2007; 148(9): 4440 - 4449. [Abstract] [Full Text] [PDF]

				M. Maghnie, B. Salati, S. Bianchi, M. Rallo, C. Tinelli, M. Autelli, G. Aimaretti, and E. Ghigo Relationship between the Morphological Evaluation of the Pituitary and the Growth Hormone (GH) Response to GH-Releasing Hormone Plus Arginine in Children and Adults with Congenital Hypopituitarism J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1574 - 1579. [Abstract] [Full Text]

				M. Shintani, Y. Ogawa, K. Ebihara, M. Aizawa-Abe, F. Miyanaga, K. Takaya, T. Hayashi, G. Inoue, K. Hosoda, M. Kojima, et al. Ghrelin, an Endogenous Growth Hormone Secretagogue, Is a Novel Orexigenic Peptide That Antagonizes Leptin Action Through the Activation of Hypothalamic Neuropeptide Y/Y1 Receptor Pathway Diabetes, February 1, 2001; 50(2): 227 - 232. [Abstract] [Full Text]

				R. D. Kineman, J. Kamegai, and L. A. Frohman Growth Hormone (GH)-Releasing Hormone (GHRH) and the GH Secretagogue (GHS), L692,585, Differentially Modulate Rat Pituitary GHS Receptor and GHRH Receptor Messenger Ribonucleic Acid Levels Endocrinology, August 1, 1999; 140(8): 3581 - 3586. [Abstract] [Full Text]

				M. Korbonits, G. Kaltsas, L. A. Perry, P. Putignano, A. B. Grossman, G. M. Besser, and P. J. Trainer The Growth Hormone Secretagogue Hexarelin Stimulates the Hypothalamo-Pituitary-Adrenal Axis via Arginine Vasopressin J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2489 - 2495. [Abstract] [Full Text]

				N. Shah, W. S. Evans, C. Y. Bowers, and J. D. Veldhuis Tripartite Neuroendocrine Activation of the Human Growth Hormone (GH) Axis in Women by Continuous 24-Hour GH-Releasing Peptide Infusion: Pulsatile, Entropic, and Nyctohemeral Mechanisms J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2140 - 2150. [Abstract] [Full Text]

				E. E. Muller, V. Locatelli, and D. Cocchi Neuroendocrine Control of Growth Hormone Secretion Physiol Rev, April 1, 1999; 79(2): 511 - 607. [Abstract] [Full Text] [PDF]

				A. Giustina and J. D. Veldhuis Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human Endocr. Rev., December 1, 1998; 19(6): 717 - 797. [Abstract] [Full Text]

				E. Arvat, R. Giordano, J. Ramunni, G. Arnaldi, A. Colao, R. Deghenghi, G. Lombardi, F. Mantero, F. Camanni, and E. Ghigo Adrenocorticotropin and Cortisol Hyperresponsiveness to Hexarelin in Patients with Cushing's Disease Bearing a Pituitary Microadenoma, But Not in Those with Macroadenoma J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4207 - 4211. [Abstract] [Full Text]

				M. Maghnie, V. Spica-Russotto, M. Cappa, M. Autelli, C. Tinelli, P. Civolani, R. Deghenghi, F. Severi, and S. Loche The Growth Hormone Response to Hexarelin in Patients with Different Hypothalamic-Pituitary Abnormalities J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3886 - 3889. [Abstract] [Full Text]

				V. Mericq, F. Cassorla, T. Salazar, A. Avila, G. Iñiguez, C. Y. Bowers, and G. R. Merriam Effects of Eight Months Treatment with Graded Doses of a Growth Hormone (GH)-Releasing Peptide in GH-Deficient Children J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2355 - 2360. [Abstract] [Full Text]

				R. G. Smith, L. H. T. Van der Ploeg, A. D. Howard, S. D. Feighner, K. Cheng, G. J. Hickey, M. J. Wyvratt Jr., M. H. Fisher, R. P. Nargund, and A. A. Patchett Peptidomimetic Regulation of Growth Hormone Secretion Endocr. Rev., October 1, 1997; 18(5): 621 - 645. [Abstract] [Full Text]

				G. Pinto, I. Netchine, M. L. Sobrier, F. Brunelle, J. C. Souberbielle, and R. Brauner Pituitary Stalk Interruption Syndrome: A Clinical-Biological-Genetic Assessment of Its Pathogenesis J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3450 - 3454. [Abstract] [Full Text] [PDF]

				G. Van den Berghe, F. de Zegher, J. D. Veldhuis, P. Wouters, M. Awouters, W. Verbruggen, M. Schetz, C. Verwaest, P. Lauwers, R. Bouillon, et al. The Somatotropic Axis in Critical Illness: Effect of Continuous Growth Hormone (GH)-Releasing Hormone and GH-Releasing Peptide-2 Infusion J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 590 - 599. [Abstract] [Full Text] [PDF]